Shaping the Future of Market Access Through Real-World Evidence and HEOR

The 3rd Annual Evidence 360 Summit — RWE, Market Access & Pricing, hosted by Veridon Global, will take place on 11–12 March 2027 in Basel, Switzerland. The summit will bring together leading decision-makers and industry experts from pharmaceutical and biotechnology companies, real-world evidence (RWE), health economics and outcomes research (HEOR), health technology assessment (HTA) organizations, payer groups, pricing and reimbursement teams, academia, and technology companies. The event will provide a dedicated platform for exploring innovative approaches to evidence generation, value demonstration, pricing strategies, and patient access to healthcare innovations.

For More Details at https://realworldevidenceconference.com/3rd-annual-evidence-360-summit-rwe-market-access-pricing-2/

As healthcare systems continue to evolve, pharmaceutical and biotechnology companies face increasing pressure to demonstrate the real-world value of their products. Regulatory developments, changing HTA practices, payer expectations, and growing demands for comparative evidence are reshaping how new therapies are evaluated and introduced into healthcare markets. In this environment, generating robust evidence is no longer simply a research activity; it is a strategic priority that directly influences market access, reimbursement decisions, pricing negotiations, and long-term product performance.

The 2027 edition of the Evidence 360 Summit will address these challenges by emphasizing a more integrated approach to evidence generation and the market access journey. Rather than treating RWE, HEOR, market access, and pricing as separate functions, the summit will explore how these disciplines can work together throughout the product lifecycle, from early-stage development and clinical research to launch, reimbursement, and post-launch evidence generation.

Integrating Evidence Generation Across the Product Lifecycle

Evidence generation plays a central role in pharmaceutical development and commercialization. While clinical trials remain essential for establishing the safety and efficacy of new therapies, decision-makers increasingly require additional evidence to understand how treatments perform in routine clinical practice, how they compare with existing alternatives, and whether their benefits justify their costs.

The Evidence 360 Summit will focus on the importance of aligning evidence strategies with market access objectives from the earliest stages of product development. Early planning can help companies identify evidence gaps, understand stakeholder expectations, and determine which clinical, economic, and real-world outcomes are most relevant to future reimbursement decisions.

By connecting evidence generation with commercial and access strategies, organizations can develop more comprehensive approaches to demonstrating the value of their products. This includes considering patient outcomes, healthcare resource utilization, treatment pathways, comparative effectiveness, and the broader economic implications of introducing new therapies.

An integrated approach can also help reduce the risk of generating evidence that fails to address the needs of payers and HTA bodies. Aligning research priorities with anticipated decision-making requirements allows teams to make more informed choices about study design, data collection, analytical methods, and evidence communication.

The Growing Importance of Real-World Evidence

Real-world evidence has become an increasingly important component of healthcare decision-making. Derived from the analysis of real-world data, RWE can provide insights into treatment effectiveness, safety, patient characteristics, healthcare utilization, and outcomes in routine clinical settings.

Unlike traditional clinical trials, which operate under defined study conditions, real-world research can help illustrate how therapies perform across broader patient populations and diverse healthcare environments. This information may support a more comprehensive understanding of treatment outcomes and complement findings from controlled clinical studies.

However, generating meaningful RWE requires careful consideration of data quality, methodological rigor, study design, and the limitations of observational research. Evidence must be sufficiently robust and relevant to address the questions posed by payers, HTA bodies, and other healthcare decision-makers.

At the summit, participants will have the opportunity to explore evolving expectations for real-world evidence, including the growing demand for comparative analyses and evidence that reflects routine clinical practice. Discussions will also examine how RWE can contribute to value demonstration, support reimbursement strategies, and inform decisions throughout the product lifecycle.

Advancing HEOR and Demonstrating Healthcare Value

Health economics and outcomes research is another critical element of evidence-based market access. As healthcare systems face increasing pressure to manage budgets while maintaining high standards of care, demonstrating the economic and clinical value of new treatments has become increasingly important.

HEOR supports the evaluation of treatment outcomes, cost-effectiveness, healthcare resource utilization, quality of life, and the broader impact of medical interventions. These insights can help decision-makers assess how a new therapy compares with available alternatives and whether its expected benefits justify the resources required for its adoption.

The summit will explore how HEOR strategies can be integrated with clinical development and real-world evidence planning to create a stronger foundation for value demonstration. This includes examining the importance of selecting relevant outcomes, understanding patient and healthcare system needs, and developing analyses that address the questions most important to healthcare decision-makers.

Beyond traditional clinical endpoints, demonstrating value may require a broader perspective that considers treatment burden, patient experience, long-term outcomes, and the potential impact on healthcare delivery. Developing evidence that captures these dimensions can help organizations communicate the value proposition of their products more effectively.

Register here at https://realworldevidenceconference.com/upcoming-conferences/uk-edition/registration/

Shaping the Future of Evidence-Driven Market Access

The 3rd Annual Evidence 360 Summit — RWE, Market Access & Pricing will provide an opportunity for industry leaders and healthcare stakeholders to examine how evidence strategies can better support pricing, reimbursement, and patient access.

Taking place on 11–12 March 2027 in Basel, Switzerland, the summit will focus on connecting evidence generation with the decisions that determine whether innovative treatments can reach the patients who need them. Through discussions on RWE, HEOR, European HTA requirements, payer expectations, value demonstration, and pricing strategies, the event will explore practical approaches to navigating an increasingly evidence-driven healthcare landscape.

Hosted by Veridon Global, the summit aims to encourage knowledge exchange and collaboration across the pharmaceutical and healthcare ecosystem. By promoting a more integrated view of evidence and access throughout the product lifecycle, the event will contribute to ongoing efforts to strengthen evidence-based decision-making and support sustainable access to healthcare innovation.